

# An antimicrobial impregnated urinary catheter that reduces mineral encrustation and prevents colonisation by multi-drug resistant organisms for up to 12 weeks

*Katherine Belfield<sup>1</sup>, Xingyong Chen<sup>2</sup>, Emily F. Smith<sup>3</sup>, Waheed Ashraf<sup>1</sup>, Roger Bayston<sup>1\*</sup>*

1. Biomaterials-Related Infection Group, School of Medicine, University of Nottingham, Nottingham, United Kingdom
2. School of Pharmacy, University of Nottingham, Nottingham, United Kingdom
3. Nanoscale and Microscale Research Centre, School of Chemistry, University of Nottingham, Nottingham, United Kingdom

**Declaration of interest:** RB is named inventor of the antimicrobial impregnation process on patents assigned to his University. He receives no remuneration from this source. No other authors have interests to declare.

**Author Contributions:** The manuscript was written through contributions of all authors. All authors have given their approval to the final version of the manuscript.

**\*Corresponding author:** Professor Roger Bayston, Biomaterials – Related Infection Group, School of Medicine, C Floor West Block, Queen’s Medical Centre, Nottingham NG7 2UH, UK. [roger.bayston@nottingham.ac.uk](mailto:roger.bayston@nottingham.ac.uk)

## 1 **Abstract**

2 Two major complications of indwelling urinary catheterisation include infection and  
3 mineral encrustation of the catheter. Our antimicrobial urinary catheter (AUC) impregnated  
4 with rifampicin, triclosan, and sparfloracin has demonstrated long-term protective activity  
5 against major uropathogens. This study aimed to firstly assess the ability of the AUC to  
6 resist mineral encrustation in the presence and absence of bacteria. Secondly, it aimed to  
7 investigate the AUC's anti-biofilm activity against multi-drug resistant organisms. There was  
8 no difference in surface roughness between AUC and control segments. In a static and a  
9 perfusion model, phosphate deposition was significantly reduced on AUCs challenged with  
10 *P. mirabilis*. Furthermore, none of the AUCs blocked during the 28 day test period, unlike  
11 controls. The AUC prevented colonisation by methicillin-resistant *Staphylococcus aureus*,  
12 methicillin-resistant *Staphylococcus epidermidis*, extended-spectrum beta-lactamase  
13 producing *E. coli*, and carbapenemase-producing *E. coli* for 12 consecutive weekly  
14 challenges. All three drugs impregnated into the catheter continued to exert protective  
15 activity throughout 12 weeks of constant perfusion. The drugs appear to migrate into the  
16 crystalline biofilm to continually protect against bacteria not in direct contact with the catheter  
17 surface. In conclusion, the AUC reduces mineral encrustation and may increase time to  
18 blockage in the presence of *P. mirabilis*, and does not predispose to mineral deposition  
19 under other conditions. It also offers 12 weeks of protection against multi-drug resistant  
20 bacteria.

21

22 **Keywords:** Urinary catheters; anti-infective agents; catheter obstruction; catheter-related  
23 infection; catheters, indwelling; microscopy, atomic force; struvite

## 24 **1 Introduction:**

25 Indwelling urinary catheters rapidly become colonised by bacteria with almost 100%  
26 of catheters colonised after 28 days<sup>1</sup>. It is important to distinguish between bacterial  
27 colonization of the catheter and catheter-associated urinary tract infection (CAUTI). Bacteria

1 in the urine without symptoms, asymptomatic bacteriuria, is not usually an indication for  
2 antibiotic treatment, but users of indwelling urethral urinary catheters are at risk of CAUTI  
3 which involves invasion of the bladder by bacteria and presence of symptoms such as  
4 bladder pain, fever, and frequency of passing urine. Patients who depend, often for life, on  
5 long term catheters (in place for 28 days or greater), are at an increased risk of repeated  
6 infections, repeated courses of antibiotics and their associated side effects, and catheter  
7 blockage caused by mineral encrustation. These problems have been compounded by the  
8 increasing role of resistant bacteria. CAUTI and its treatment have profound effects on  
9 quality of life, mental health, and associated costs.

10 All urinary catheter types are susceptible to mineral encrustation, a complication resulting  
11 from crystal deposits on the catheter surface[1]. Some bacteria produce urease, an enzyme  
12 which hydrolyses urea from the urine into ammonia and carbon dioxide. The production of  
13 ammonia results in an alkaline urinary pH, causing precipitation of urinary minerals such as  
14 calcium, magnesium, and phosphate and their deposition on the catheter surfaces[2].  
15 Crystal deposits can occlude the catheter lumen or drainage eyelets causing reflux of urine  
16 to the kidneys and/or bypass of urine around the outside of the catheter[2, 3]. Some catheter  
17 users experience blockages as frequently as every seven to 10 days[4].

18 Urease-producing uropathogens include *Proteus* spp., *Morganella morganii*,  
19 *Staphylococcus aureus*, and *Staphylococcus saprophyticus*[2]. *P. mirabilis* is most frequently  
20 cited as the cause of encrustation and catheter blockage due to the ability of its urease to  
21 hydrolyse urea six-25 times faster than ureases from other species[5]. *P. mirabilis* forms a  
22 crystalline biofilm in which the biofilm bacteria grow amongst ammonium magnesium  
23 phosphate (struvite) and calcium phosphate crystals[6]. The polysaccharide matrix formed  
24 by *P. mirabilis* biofilm initiates crystallisation by binding calcium and magnesium ions and is  
25 thus able to maintain crystallisation and encrustation of the catheter[7].

26 The clinical, personal, and financial burden of CAUTI and subsequent blockages is vast  
27 and yet no commercial technology exists to prevent CAUTI in patients who require long-term  
28 indwelling urinary catheters (more than 28 days) to manage their bladder. Costs and

1 morbidity are further increased if CAUTI is caused by a multi-drug resistant organism[8]. A  
2 multi-centre randomised controlled trial of a commercially available silver-alloy catheter and  
3 a previously available nitrofurazone-coated catheter for use under 28 days did not  
4 significantly reduce clinical episodes of CAUTI[9]. A commercially available 0.3% triclosan  
5 balloon inflation fluid intended to reduce mineral encrustation and blockage due to the  
6 activity of triclosan against *Proteus mirabilis*[10], has recently become available, but this  
7 technology is suitable only for short-term use. There are no anti-infective or anti-encrustation  
8 catheters for long-term use.

9 An antimicrobial urinary catheter (AUC) with protective activity for the lifetime of a long-  
10 term urinary catheter (up to 12 weeks) has been developed in an effort to provide long-term  
11 protection [11]. The drug release profile and drug distribution in silicone urinary catheters  
12 impregnated with rifampicin, triclosan, and sparfloxacin have been previously characterised  
13 [11, 12]. Importantly, these initial assessments demonstrated that antimicrobial impregnation  
14 of silicone urinary catheters did not adversely affect the mechanical properties of the  
15 catheter nor inflation and deflation of the balloon. Time-of-flight secondary ion mass  
16 spectrometry studies indicated that the drug molecules are impregnated throughout the  
17 silicone material including the intraluminal surface, extraluminal surface, and balloon. The  
18 AUC has demonstrated between seven and 12 weeks of protection against bacterial  
19 colonisation in a clinically predictive in vitro flow model [11]. The AUC aims to avoid the  
20 development of resistance by using antimicrobials locally and not systemically, and by  
21 optimising its design in line with the Dual Drug Principle. This states that the use of two  
22 antibiotics of two different classes prevents emergence of resistance, as the likelihood of  
23 bacteria developing two simultaneous mutations is greatly reduced[13].

24 This study further aims to understand firstly if the antimicrobial impregnation process  
25 affects the surface roughness of the catheter, which if increased may predispose the AUC to  
26 increased crystallisation and encrustation. Surface roughness was quantified by atomic force  
27 microscopy, and as a consequence of surface changes, phosphate deposition on the  
28 catheter surface was measured in the absence and presence of urease-producing bacteria.

1 The test bacteria included *P. mirabilis* as it represents a robust crystalline biofilm former with  
2 an efficient urease enzyme. *S. saprophyticus* also produces a urease enzyme but one that is  
3 less efficient than that of *P. mirabilis*, and served as an example of an uropathogen with  
4 moderate urease activity. *E. coli* is the most common causative organism of CAUTI but does  
5 not produce urease and was the urease-negative control. Secondly, this study investigated  
6 the efficacy of the AUC against multi-drug resistant (MDR) gram-positive and gram-negative  
7 organisms including methicillin-resistant *S. aureus* (MRSA) and carbapenemase-producing  
8 *E. coli*, which are resistant to the newer antimicrobials developed for use against such  
9 bacteria.

10

## 11 **2 Materials and Methods**

### 12 **2.1 Antimicrobial impregnation of silicone urinary catheters**

13 The method of antimicrobial impregnation of silicone materials has been previously  
14 described [14, 15]. Briefly, 1.0% w/v triclosan (Irgasan, BASF Ludwigshafen, Germany),  
15 0.2% w/v rifampicin (Sigma), and 1.0% w/v sparfloxacin (Sigma-Aldrich) were dissolved in  
16 chloroform (Analytical reagent grade, Fisher Scientific, Loughborough, United Kingdom).  
17 Silicone catheters (16 Ch BARDIA® AQUAFIL®, Bard Medical), with any plastic components  
18 removed, were immersed in the antimicrobial-chloroform solution for one hour, after which  
19 they were removed and the chloroform was evaporated under constant air flow for at least  
20 12 hours. The catheters were rinsed in absolute ethanol (Fisher Scientific) to remove any  
21 surface aggregates. Catheters or 1.0 cm longitudinally cut segments were sterilized by  
22 autoclaving at 121°C for 15 minutes.

23

### 24 **2.2 Isolation and characterization of uropathogens for encrustation** 25 **studies**

26 F2627 *S. saprophyticus*, F2647 *E. coli*, and F2629 *P. mirabilis* were isolated from  
27 indwelling urinary catheters and ureteral stents collected at Nottingham University Hospitals

1 NHS Trust, Nottingham, United Kingdom. General microbiological identification, including  
2 urease production, was performed and identification was confirmed by API (BioMerieux,  
3 Marcy l'Etoile, France). Antimicrobial susceptibility testing was carried out according to  
4 EUCAST guidelines[16].

5

## 6 2.3 Isolation and characterisation of MDR uropathogens for efficacy 7 studies

8 Bacteria of interest were isolated from clinically relevant samples, particularly from  
9 the lumens of urinary catheters and ureteral stents collected at Nottingham University  
10 Hospitals NHS Trust, Nottingham UK. A New Delhi metallo-beta-lactamase (NDM-1)  
11 producing *E. coli* isolated from a mid-stream urine specimen was donated by NHS Dumfries  
12 and Galloway. General microbiological identification was performed and identities were  
13 verified by API (Biomérieux).

14 Antimicrobial susceptibility testing was carried out according to the EUCAST  
15 guidelines[16, 17]. Methicillin resistance by staphylococci was determined by disc diffusion  
16 using a ceftaxime disc (30 µg) on Mueller-Hinton agar (MHA) (Oxoid). *E. coli* were screened  
17 for extended-spectrum beta-lactamase (ESBL) production by disc diffusion using cefpodoxime  
18 (10 µg), ceftazidime (10 µg), ceftriaxone (5 µg) discs (Oxoid Ltd., Basingstoke, United  
19 Kingdom) Confirmatory testing was carried out using the gradient test method using both  
20 cefotaxime/cefotaxime + clavulanic acid and ceftazidime/ceftazidime + clavulanic acid strips  
21 (Etest, Biomérieux) on MHA. Carbapenemase production was detected initially by disc  
22 diffusion to meropenem (10 µg). Specific metallo-beta-lactamase (MBL) activity was  
23 detected using the Total Metallo-beta-lactamase Confirm Kit: MBLs (Rosco Diagnostica,  
24 Taastrup, Denmark) and the procedure and interpretation of results were carried out  
25 according to the manufacturer's instructions. The precise MBL was verified by the  
26 Antimicrobial Resistance and Healthcare Associated Infections Reference Unit (London,  
27 United Kingdom)[18].

1           The bacterial test panel included F4001 methicillin-resistant *S. epidermidis* (MRSE),  
2 F4142 methicillin-resistant *S. aureus* (MRSA), F3991 methicillin-susceptible *S. aureus*  
3 (MSSA), F3802 NDM-1 producing *E. coli*, and F3986 ESBL- producing *E. coli*.

## 5   2.4 Bacterial attachment assay

6           A bacterial attachment assay was used to verify the ability of the test bacteria to attach  
7 and remain attached to silicone that would be used in the subsequent models[19, 20].  
8 Bacterial attachment to 1.0 cm longitudinally cut silicone catheter segments was quantified  
9 by detaching bacteria into surrounding 1.0 mL PBS by unheated sonication for five mins at  
10 50 kHz (Precision Ultrasonic Cleaner DP201-00, Ultrwave Ltd., Cardiff, UK). Previous  
11 validation in our laboratory showed that sonication for five minutes achieved the best  
12 balance of detaching bacteria without killing bacteria[21]. Further details can be found in  
13 Supplementary Methods 1.

## 15 2.5 Encrustation studies

### 16 2.5.1 Atomic force microscopy

17           Artificial urine (AU) was prepared according to the formula by Griffith et al[22] and  
18 adjusted to a pH of 6.1 (urinary pH ranges from 5.52-6.97 in adults [23]) before being filter  
19 sterilised. 1.0 cm longitudinally cut segments in triplicate were added to the AU and incubated  
20 at 37°C with rocking for either one hour, one week, or two weeks. Sterile, fresh AUCs and  
21 silicone segments without soaking were included as controls. A chloroform-only control was  
22 also used, as its swelling action on silicone could have altered the surface in the absence of  
23 antimicrobial molecules.

24           For imaging by AFM, a small section of the 1.0 cm longitudinally cut catheter segment  
25 was cut away and placed on a microscope glass slide with the lumen side facing up. The  
26 slide was pre-coated with Araldite glue and dried. Three separate samples from each  
27 experimental group were imaged using a Bruker ICON FastScan Bio microscope in

1 Peakforce in air mode using Tap150A tips with an 8nm radius. Image preparation and  
2 surface roughness analysis were carried out using Nanoscope Analysis v1.5 software  
3 (Bruker Corporation, Massachusetts, USA).

#### 5 2.5.2 Investigation of mineral encrustation prevention – static model

6 Phosphate precipitation was measured by a colourimetric assay based on the method by  
7 Mahadevaiah et al[24]. Disodium hydrogen phosphate in increasing concentrations was  
8 added to 0.5 mL of  $5.528 \times 10^{-3}$  M ammonium molybdate (Hopkin and Williams, Essex, UK)  
9 and 3.0 mL 0.25 N sulphuric acid (Fisher Scientific) to create the calibration plot. 1.0 mL of  
10  $2.0833 \times 10^{-3}$  M sodium sulphide (Scientific Laboratory Supplies, Nottingham UK) was added  
11 and the solution was incubated at room temperature (20-25°C) for 20 minutes. Absorbance  
12 was measured against milliQ water by spectrophotometer (Jenway UV/Vis, Staffordshire,  
13 UK) at 715 nm.

14 F2629 *P. mirabilis*, F2627 *S. saprophyticus*, and F2647 *E. coli* were subcultured on blood  
15 agar overnight at 37°C. A loopful of the fresh culture in 20.0 mL tryptone soya broth (TSB,  
16 Oxoid) was incubated for four hours at 37°C with shaking at 200 rpm (Orbital Incubator  
17 1500, Stuart, Staffordshire UK). The bacterial suspension was adjusted to  $A_{490}$  0.6 – 0.7 and  
18 5.0  $\mu$ L was added to 50.0 mL filter-sterilised AU (adjusted to pH of 6.1) in triplicate. An  
19 additional 50.0 mL filter-sterilised AU adjusted to a pH of 6.1, 7.1, or 8.3 using 1 M sodium  
20 hydroxide (Fisher Scientific) was also prepared.

21 1.0 mL of the bacterial inoculated AU or the pH-adjusted AU was added to 1.5 mL  
22 microcentrifuge tubes in triplicate. At 0, 4, 24, 48 and 72 hours the phosphate precipitate  
23 was harvested by centrifugation (3000 rpm for five minutes) (Centaur 2 Centrifuge, MSE,  
24 Sussex, UK), and resuspended in 1.0 mL sterile milliQ water. The 1.0 mL suspension was  
25 added to the reagents described previously and spectrophotometrically measured. The assay  
26 was repeated in which 1.0 mL of bacterial inoculated AU or pH-adjusted AU was added to  
27 1.0 cm longitudinally cut AUC segments or silicone segments and incubated at 37°C with



1 shaking at 200 rpm for 0, 4, 24, 48, or 72 hours. For each time point the phosphate attached  
2 to three catheter segments was harvested by sonication in 1.0 mL sterile milliQ water for five  
3 minutes. The sonicate was transferred to the reagents described previously and measured  
4 by spectrophotometer.

5

### 6 2.5.3 Investigation of mineral encrustation prevention – In vitro flow model

7 A clinically predictive in vitro flow model has been previously described in the  
8 literature [20] [19] [25]. AU was perfused through silicone catheters and AUCs to determine  
9 the time to blockage and phosphate deposition on the catheter lumens in the presence and  
10 absence of *P. mirabilis*. Briefly, the AUCs in triplicate (with balloon and drainage ports  
11 removed) with an all-silicone control were aseptically inserted into a multi-chamber water  
12 jacket. The water jacket was maintained at 37°C by a heating circuit. AU was pumped  
13 through the catheters at a rate of 30 mL/hour [26] using a peristaltic pump (Watson-Marlow  
14 Ltd., Falmouth, UK) which regulated flow (Figure 1). The waste AU was collected in a 30 L  
15 waste collection container. Control and experimental catheters were challenged weekly with  
16 an early log phase culture of 10<sup>5</sup> CFU/mL inoculum. AU was perfused through the catheters  
17 for one hour to prime the tubing and form a conditioning film. 2.0mL of the inoculum was  
18 inserted into the catheter tubing and was retained in the catheter tubing for one hour to allow  
19 bacterial attachment by clamping (straight-jaw surgical clamps) tubing 2 and tubing 4 in  
20 close proximity to the catheter tubing. Flow was then restarted. This was carried out weekly  
21 for each challenge.

22

23 Bacterial growth was monitored for each control and AUC after inoculation and then  
24 daily by disconnecting the outlet tubing and collecting the effluent into a sterile bijou bottle  
25 (Sterilin). The collected effluent and its dilutions were spread onto cysteine-lactose-  
26 electrolyte-deficient agar (Oxoid) for *P. mirabilis* and onto blood agar for the other isolates.  
27 The plates were incubated overnight and colonies were enumerated.

1        The in vitro challenge model ran for 28 days or until blockage of the catheter, which was  
2 determined by leaking proximal to the test catheter and subsequent examination by  
3 microscope of the catheter lumen for occlusion. One 1.0 cm long segment of the catheter  
4 tubing was cut away from an area within the water jacket using a sterile scalpel, placed in  
5 2.0 mL of cold acetone, and refrigerated for scanning electron microscopy (SEM). Another  
6 was cut away and placed in a clean, dry glass bottle for x-ray photoelectron spectroscopy  
7 (XPS).

8        The remaining section of the catheter tubing was dried at 40°C for 24 hours. After drying,  
9 the catheter tubing was filled with approximately 1.0 mL of milliQ water and the ends were  
10 clamped. The clamped tubing was sonicated for five minutes at 50 kHz. The sonicate was  
11 drained into a sterile bijoux bottle and was added to the colourimetric reagents described  
12 above and measured spectrophotometrically at 715 nm. The minimum level of detection was  
13 2.2 ppm.

14

#### 15 2.5.4 Scanning electron microscopy

16        Fixed 1.0 cm catheter segments were cut longitudinally using a sterile scalpel to  
17 expose the inner lumen. The lumen samples were dehydrated by tetramethylsilane (Sigma-  
18 Aldrich) [27] and fixed onto specimen stubs (12.5 mm diameter, Agar Scientific, Stansted,  
19 UK). The samples were gold sputter-coated for 300 seconds and imaged using a Jeol JSM-  
20 6060 scanning electron microscope (JEOL Ltd., Tokyo, Japan). The accelerating voltage  
21 was 30 kV and working distance was 10.0mm at x65 magnification.

22

## 23 2.6 Efficacy studies

### 24 2.6.1 In vitro flow model

25        The same in vitro flow model as described previously was employed to determine the  
26 ability of the AUC to resist bacterial colonisation. 20% aqueous TSB was used as the  
27 perfusion medium instead of AU as it has similar peptide and amino acid content and a

1 similar pH (6.9 at 24.4°C) at this concentration but is more convenient to produce in  
2 significant quantities. AUCs in triplicate and a control catheter were challenged by each  
3 microorganism weekly as described previously. The in vitro flow model ran until the end of  
4 12 weeks or until the AUCs became colonised, which was determined by counting colonies  
5 in the effluent from each catheter daily. Success in the in vitro flow model, eradication of the  
6 attached microorganisms, was determined as CFU/mL = 0 of the test organism in the  
7 effluent at the end of the weekly challenge period.

8

### 9 2.6.2 High-performance liquid chromatography

10 AUCs were removed from the in vitro flow challenge model at failure or at the end of  
11 12 weeks and kept at -20°C until drug extraction. Freshly impregnated unperfused catheters  
12 were also processed. Drug was extracted from three 1.0 cm long catheter segments in  
13 chloroform. The drug extraction process was repeated three times for each segment to  
14 ensure complete drug extraction and the extracts in chloroform per sample were pooled  
15 together. The chloroform was evaporated off and drug residues were stored at -20°C until  
16 reconstitution with methanol. HPLC analysis was performed by an Agilent 1100 HPLC  
17 machine with a variable wavelength UV detector (Agilent Technologies, Berkshire, UK)  
18 (Supplementary Method 2). Standards of all three drugs were prepared in methanol. All  
19 experiments were carried out in triplicate and the calibration curves demonstrated good  
20 linearity with R<sup>2</sup> values of >0.990 for all curves.

21

### 22 2.6.3 XPS Analysis

23 The AUCs and control segments perfused with AU and challenged with *P. mirabilis*  
24 were further assessed for drug content at the exposed surface. Catheter segments exposed  
25 to *P. mirabilis* were chosen due to the robust nature of the *P. mirabilis* crystalline biofilm  
26 which may form a thick mineral layer on the catheter surface. If there are minerals, a  
27 proteinaceous conditioning film, or biofilm on the catheter surface it is important to

1 understand if the antimicrobials can migrate through the surface deposits to exert their  
2 antimicrobial effect. Catheters were stored in clean glass vials until processing by a Kratos  
3 AXIS ULTRA instrument with a monochromated Al  $K\alpha$  X-ray source (1486.6eV). The 1.0 cm  
4 catheter segments were cut longitudinally using a clean, sterile scalpel. Samples were  
5 mounted lumen side-up on a Kratos sample bar with double-sided tape (Sellotape). The  
6 sample bar was inserted into the airlock and the pressure was pumped to approximately  $3 \times$   
7  $10^{-7}$  Torr overnight. It was transferred to the analysis chamber where the pressure remained  
8 at  $5 \times 10^{-9}$  Torr or less. Two areas of approximately  $700 \times 300 \mu\text{m}$  from the catheter lumens  
9 were analysed with low resolution wide scan at pass energy 80 eV and high resolution  
10 spectra at pass energy 20 eV on relevant energy ranges for the elements detected. The data  
11 were collected using Kratos VISIONII software and processed with CASAXPS software  
12 (version 2.3.17) with Kratos relative sensitivity factors.

13

## 14 2.7 Statistical analysis

15 Graphing and statistical analysis were carried out using GraphPad Prism 7.0 (GraphPad  
16 Software Inc., La Jolla California, USA). Data analysed using unpaired multiple comparisons  
17 t-tests were corrected for using the Holm-Sidak method and  $p < 0.05$  was considered  
18 significant.

19

## 20 3 Results

### 21 3.1 Bacterial attachment screening assay

22 The three encrustation strains and five efficacy test bacteria were able to attach and  
23 maintain attachment to silicone urinary catheters over 72 hours (data not shown).

24

## 1 3.2 Encrustation studies

### 2 3.2.1 Atomic force microscopy

3 The surface of a silicone, non-soaked catheter appeared to be composed of nano-sized  
4 peaks and spikes (see Figure 2a for examples of images generated by AFM analysis of  
5 silicone controls and AUC segments). The spiky surface is apparent after soaking at all three  
6 time points and remains consistent. Of interest, the appearance of the AUC segments  
7 without soaking compared to the silicone catheters has a different appearance despite mean  
8 surface roughness values as represented by the root mean square roughness ( $R_q$ ) values of  
9  $34.77 \pm 5.95$  and  $56.6 \pm 14.09$  respectively, which were not significantly different across  
10 groups according to one-way ANOVA of  $p=0.0806$  (Figure 2b). Despite having non -  
11 significantly different  $R_q$  values to the silicone segments, the surface of the non-soaked AUC  
12 segments appears to have less numerous sharp spikes and instead fewer spikes, but wider,  
13 flatter areas. The same can be said of the silicone and AUC segments soaked for one hour  
14 in which there is no significant difference between group means, but the topography of the  
15 AUC 1 hr soaked segments is composed of more plateaus and fewer spikes compared to  
16 the silicone 1 hr soaked segments.

17 An important limitation of this method is that of the 1.0 cm longitudinally cut catheter  
18 segments, only a  $2.0 \mu\text{m} \times 2.0 \mu\text{m}$  area is measured and quantified so it is possible that  
19 chance would allow for rougher or smoother areas to be sampled, which may be responsible  
20 for the large standard deviation for the AUC – 1 wk group. This outlying group also does not  
21 correspond to the mean values of AUC – 1 hr and AUC – 2 wks, which were not significantly  
22 different from the Control (No soaking) mean, and in fact it would be expected that those  
23 segments soaked for two weeks would have a greater surface roughness than those soaked  
24 for one week. The  $R_q$  values for the all-silicone segments soaked for one week (Plain – 1  
25 wk) were consistent with the control and all-silicone segments soaked for one hour and  
26 soaked for two weeks.

### 1 3.2.2 Static model of encrustation

2 The mean of the optical density values was interpolated from the calibration plot to  
3 give the amount of phosphate precipitated from the AU adjusted to a pH of 6.1, 7.1, or 8.3.  
4 Figure 3a shows that the method has the sensitivity to detect differences in phosphate  
5 precipitation under different conditions. At 48 hours  $1347.0 \pm 76.33$  mg/L,  $697.1 \pm 78.81$  mg/L  
6 and  $359.1 \pm 201.9$  mg/L of phosphate were precipitated from AU adjusted to pH of 8.3, 7.1,  
7 and 6.1 respectively. Phosphate precipitation in the presence of the three bacteria appeared  
8 to be influenced by the activity of the urease enzyme and its ability to moderate the urinary  
9 pH as expected (Figure 3b).

10  
11 Significantly less phosphate was attached to the AUC segments incubated with *P.*  
12 *mirabilis* at 48 hours ( $p=0.004$ , unpaired t-test), 72 hours ( $p=0.007$ ), and 96 hours ( $p=0.011$ )  
13 compared to the control catheter segments (Figure 4). Phosphate attached to the control  
14 and AUCs was not significantly different from those catheter segments incubated in AU with  
15 *S. saprophyticus*, *E. coli* or AU adjusted to the three different pH values. This suggests that  
16 the antimicrobial impregnation process reduces mineral deposition on the catheter surface in  
17 the presence of *P. mirabilis*.

### 18 19 3.2.3 In vitro flow model of encrustation

20 All control catheters inoculated with *P. mirabilis* blocked before the end of the 28  
21 days test period. The average time until blockage was 21.7 days (range 16-26 days). None  
22 of the AUCs blocked during this time period. The corresponding AUC was removed from the  
23 model for analysis at the time of control catheter blockage. The amount of phosphate  
24 attached to the lumens of the AUCs perfused with AU inoculated with *P. mirabilis* was  
25 significantly less ( $p=0.0197$ , paired t-test) than the phosphate attached to the control  
26 catheters. These results correspond to the findings of the static model, in that the AUC is  
27 able to reduce phosphate attachment in the presence of *P. mirabilis*.

1           None of the AUCs or silicone controls perfused with AU only (without *P. mirabilis*)  
2 blocked within the 28 day test period. In the absence of bacteria, there is no significant  
3 difference ( $p=0.599$ , paired t-test) between the amount of phosphate attached to the AUC  
4 and silicone catheters after being exposed to flow conditions for 28 days which corresponds  
5 to the results of the static model of encrustation as there was no significant difference in  
6 phosphate deposition between the AUC and silicone control catheter segments in the  
7 absence of bacteria.

8

### 9 3.2.4 Scanning electron microscopy of catheters in the flow model

10           SEM images showed fewer deposits on AUC lumens compared to the matched  
11 silicone catheter lumens when inoculated with *P. mirabilis*. For example, the AUCs removed  
12 at 23 and 16 days when the silicone controls blocked, were virtually free of mineral deposits.  
13 The catheters removed at 26 days had more mineralisation on the catheter surface  
14 compared to the others removed earlier. However, the AUC had a single layer of widely  
15 spaced minerals, whereas the silicone matched control had much larger three-dimensional  
16 clusters of minerals (Figure 5). While SEM is not quantitative, it does provide visual  
17 indications of the reduction of mineral deposition of the AUC surfaces when inoculated with  
18 *P. mirabilis*.

19

## 20 3.3 Efficacy studies

### 21 3.3.1 In vitro flow challenge model

22           The AUC prevented colonisation by MSSA, MRSE, ESBL *E. coli* and NDM-1 *E. coli*  
23 (Figure 6a) for 12 weeks and prevented colonisation by MRSA for 10-12 weeks (Figure 6b).  
24 In the case of MRSA, at 11 weeks one catheter failed to kill 100% of bacteria during the  
25 challenge period, another failed at 12 weeks, and the third catheter successfully prevented  
26 colonisation for the entire 12-week experimental period. The control catheters were  
27 successfully colonised by the bacterial isolates each week indicating that the bacterial  
28 isolates were capable of attachment and colonisation throughout the test period.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

### 3.3.2 HPLC

HPLC Drug content analysis of catheter segments before and after constant perfusion and bacterial challenge for 12-13 weeks showed that sparfloxacin and triclosan were readily detectable in the catheter segments. Rifampicin was detectable after perfusion in the majority of catheters, but the amount was often below the limit of quantification. A summary of the drug content of AUCs after 12-13 weeks of perfusion and bacterial challenge can be found in Table 1. The majority of each drug was eluted over 12-13 weeks so that some detectable drug remained, but the majority had been eluted. This data combined with that from the in vitro flow model suggests that the remaining amount is sufficient to offer protection, but that the antimicrobials are eluted at a rate such that they are exhausted at the end of catheter lifetime.

**Table 1:** Proportional drug content (w/w) and total drug content (mg) with interquartile range (IQR) of silicone catheters impregnated with rifampicin, sparfloxacin, and triclosan and after constant perfusion and weekly bacterial challenge for 12-13 weeks.

	Drug content at impregnation		Drug content after 12-13 weeks perfusion		Drug eluted over period of perfusion	
	Median proportional drug content (w/w) (IQR)	Total drug content (mg) (IQR)	Median proportional drug content (w/w) (IQR)	Total drug content (mg) (IQR)	Median proportional drug eluted	Median drug eluted (mg)
<b>Rifampicin</b>	0.080% (0.013%)	8.81 (5.08)	0.0046%* (0.0029%)	0.51* (0.33)	94.09%*	8.29*
<b>Sparfloxacin</b>	0.70% (0.16%)	90.83 (34.88)	0.20% (0.10%)	22.41 (11.21)	75.33%	68.42
<b>Triclosan</b>	1.08% (0.14%)	121.99 (40.9)	0.021% (0.023%)	2.33 (2.55)	98.09%	119.66

\* indicates rifampicin samples below the limit of detection and quantification were not included in the calculation

17  
18  
19

### 3.3.3 XPS analysis

XPS is a surface-sensitive technique, detecting the uppermost 10 nm of the sample, therefore it is uniquely sensitive to thin film formation on a silicone surface. XPS is also sensitive to the light elements (C, N, and O) and exhibits chemical shifting of the detected peaks dependent on the chemical environment of these light atoms. From Table 2 the



1 principal detected elements are O, C, and Si, which are the detectable elements of  
 2 silicone[28]. It appears that some of the surface analysed has a film thickness of less than  
 3 10 nm or that the biofilm/mineral encrustations are patchy and bare areas of silicone are  
 4 detectable. As there was 50.0% and greater C in all samples, the extra carbon is a likely  
 5 result of deposition of cellular and organic material. The O and Si were slightly less than  
 6 25% consistently and this is probably due to cells and mineral deposits that prevented some  
 7 of the catheter surfaces from being detected. Phosphorous (P) and calcium (Ca) are  
 8 markers of mineral encrustation and Ca is significantly reduced ( $p=0.0281$ , post-hoc (one-  
 9 way ANOVA) multiple comparisons with Dunnett's correction) on the AUCs exposed to *P.*  
 10 *mirabilis* compared to control catheters exposed to *P. mirabilis*. Although there was no  
 11 statistically significant difference in P between groups ( $p=0.1165$ , one-way ANOVA), no P  
 12 was detected on AUCs exposed to *P. mirabilis*. This reinforces the results of the other  
 13 assays that the AUC reduces mineral encrustation.

14 **Table 2:** X-ray photoelectron spectroscopy. Mean and standard deviation of atomic %  
 15 estimated from the photoelectron peak intensities composition of silicone (Plain) and  
 16 antimicrobial-impregnated urinary catheter catheter (AUC) segments perfused with artificial  
 17 urine alone (AU) or artificial urine inoculated with *Proteus mirabilis* (Proteus) for 28 days. C:  
 18 Carbon, O: oxygen, Si: Silicon, Cl: chlorine, N: nitrogen, F: fluorine, P: phosphorous, Ca:  
 19 calcium  
 20  
 21

	C 1s	O 1s	Si 2p	Cl 2p	F 1s	N 1s	P 2p	Ca 2p
AUC Proteus	56.4 ± 3.3	21.7 ± 2.3	17.2 ± 1.4	0.4 ± 0.3	1.1 ± 0.3	2.9 ± 0.2	0	0.05 ± 0.08
Plain Proteus	53.3 ± 1.3	24.1 ± 0.4	16.3 ± 6.7	0.7 ± 0.6	0	3.8 ± 3.7	0.6 ± 0.6	0.5 ± 0.3
AUC AU	53.5 ± 1.5	23.7 ± 1.9	19.2 ± 1.7	0.2 ± 0.2	1.00 ± 0.5	2.0 ± 0.6	0.1 ± 0.2	0.1 ± 0.08
Plain AU	52.3 ± 2.1	24.7 ± 0.6	21.5 ± 2.3	0.03 ± 0.06	0	1.0 ± 0.7	0.02 ± 0.03	0.1 ± 0.06

22  
 23 Fluorine (F), an elemental component of sparfloxacin, was detected only in the AUC  
 24 segments supporting the view that the antimicrobials at the surface were detected by XPS.  
 25 There is no F in the AU formula. The amount of N detected varied between 1.0-3.8 atomic %  
 26 (Table 2). There are three possible contributions to the N 1s peak, namely; antibiotics  
 27 (rifampicin and sparfloxacin), urea in the form of NH<sub>2</sub>, and proteins. The dosing of the  
 28 antibiotics into the silicones is relatively low so a very small N 1s contribution from the

1 antimicrobials is expected even for an unexposed catheter. The catheter spectra discussed  
2 herein are all for materials exposed to AU and, therefore, are likely to have some coverage  
3 of biofilm or encrustation, and most of the N 1s signal is likely to come from that. In all four  
4 samples, the N1s peak consists of a low binding energy at approximately 400 eV consistent  
5 with ureic acid and a higher binding energy at approximately 402 eV, which can be attributed  
6 to several possible forms of polymeric nitrogen[29]. The peak positions observed exclude the  
7 possibility of nitride and nitrate forms, which would be at lower and higher binding energies,  
8 respectively, than the observed peaks. It is difficult to accurately interpret the origin of the  
9 nitrogen species, however, as stated, they are consistent with the expected urea and  
10 proteins from cell growth on the catheter surface[30]. The amount of N can be taken as a  
11 rough guide to the severity of growth and should correlate with other assessment methods.  
12

#### 13 **4 Discussion:**

14 In this study, silicone urinary catheters impregnated with 0.080% w/w rifampicin,  
15 0.704% w/w sparfloxacin, and 1.084% w/w triclosan were investigated for their surface  
16 roughness properties and propensity for mineral encrustation and ability to resist  
17 colonisation by MDR organisms. These studies determined that surface roughness was not  
18 affected by the antimicrobial impregnation process or by depletion of the antimicrobial  
19 molecules over time. When exposed to bacteria with increasing urease activity and artificial  
20 urine of three increasingly alkaline concentrations mineral encrustation (as measured by  
21 phosphate) did not significantly differ between silicone control and antimicrobial impregnated  
22 catheters. There was significantly less mineral deposition on the antimicrobial impregnated  
23 catheters inoculated with *P. mirabilis* compared to the control inoculated with *P. mirabilis* 24-  
24 72 hours after exposure to the bacterial-AU inoculum. Of interest, there was increased  
25 phosphate attachment universally to the AUCs in the presence and absence of bacteria at 0  
26 and 4 hours compared to the controls. Before soaking and at 0 hours, the AUCs are  
27 considerably more hydrophilic (water contact angle of  $79.95^\circ \pm 3.88^\circ$ ) than silicone controls  
28 (water contact angle of  $90.68^\circ \pm 0.85$ ) [12]. Hydrophilic surfaces have a greater surface

1 energy which may serve to attract phosphate, however, within 24 hours phosphate  
2 attachment is reduced to less or no different from the controls. The anti-encrustation  
3 properties of the AUC in the presence of *P. mirabilis* were investigated in a flow model which  
4 demonstrated that the AUC prevented blockage and significantly reduced mineral  
5 encrustation. This was further examined by SEM.

6 The AUCs and controls were challenged weekly for 12-13 weeks with MDR *S.*  
7 *aureus* and *E. coli* in the in vitro flow challenge model and prevented colonisation by ESBL  
8 *E. coli*, NDM-1 *E. coli*, MSSA, and MRSE for 12-13 weeks and prevented colonisation by  
9 MRSA for 10-12 weeks. The mechanism of colonisation prevention was investigated by XPS  
10 and HPLC. XPS demonstrated the presence of fluorine atoms in conditioning films on AUCs  
11 and not on the control catheters suggesting sparfloxacin as the source. Nitrogen was  
12 present on the surfaces of all experimental and control catheters, but the shape of the peaks  
13 from AUCs was different to the control catheters suggesting rifampicin and sparfloxacin as a  
14 source of nitrogen contributing to the peak shape. HPLC demonstrated the presence of the  
15 antimicrobials in the AUCs after 12-13 weeks of perfusion in amounts that were greatly  
16 reduced compared to the amount initially impregnated. This is important to the design of the  
17 catheter as it demonstrates a balance of having enough drug molecules to protect the  
18 catheter, but also that it has allowed diffusion through the silicone to replace molecules that  
19 have been rinsed away by flow.

20

#### 21 4.1 Encrustation studies

22 AFM studies demonstrated that neither antimicrobial impregnation nor soaking to  
23 deplete surface molecules resulted in significant differences in surface roughness values.  
24 This may be clinically relevant to mineral encrustation as an increase in surface roughness  
25 or depressions may increase the number of nuclei available to initiate the crystallisation  
26 process[31, 32]. This hypothesis is supported by Santin et al., in which they perfused  
27 hydrogel-coated ureteral stents with concentrated urine and commented that the hydrogel-

1 coating was degraded by the urine and that this ‘...[favoured] the formation of irregularities  
2 on the surface which may represent preferential sites for the massive deposition of organic  
3 matter for the nucleation of crystals’[33].

4         Therefore, the mineral encrustation/crystallisation potential of the AUC was  
5 investigated in a clinically predictive flow model using artificial urine, which is a consistent,  
6 reproducible medium unlike urine from donors, replicates the protein content of urine[34] and  
7 produces a conditioning film that replicates in vivo urological conditioning films[11, 35]. AU  
8 has also been shown to produce crystals similar to those found in human urine[36]. A  
9 spectrophotocolourimetric method was employed to quantify phosphate deposition on the  
10 catheter surfaces as phosphate is a key component of struvite crystals ( $\text{NH}_4\text{MgPO}_4 \cdot 6\text{H}_2\text{O}$ ),  
11 which are often the byproduct of urease - producing bacteria, amorphous phosphate crystals  
12 which are formed in alkaline urine, and of calcium phosphate, which is a key component of  
13 urinary stones[37]. The extent of mineral encrustation has been previously detected using  
14 atomic absorption spectroscopy[3, 38, 39]. However, a key disadvantage is that phosphate  
15 interferes with the detection of calcium[40], another common component of urinary crystals,  
16 and phosphate is difficult to detect as the wavelength required to excite phosphorous  
17 electrons is within the ultraviolet spectrum[41]. Therefore, atomic absorption spectroscopy  
18 typically measures magnesium and calcium, and calcium detection may be reduced in the  
19 presence of phosphate. A spectrophotocolourimetric method was advantageous as it is  
20 relatively simple and inexpensive so many samples can be analysed, and phosphate could  
21 be quantified.

22         The method relies on the formation of phosphomolybdate ( $(\text{PO}_4\text{Mo}_{12})^{3-}$ ), which creates  
23 a blue colour, the intensity of which can be measured[24] and correlated to phosphate  
24 concentration according to Beer-Lambert’s law[42]. The method was validated for the  
25 purposes of these experiments by measuring phosphate precipitation in AU when in the  
26 presence of bacteria and pH-adjusted AU. The minimum limit of detection was 2.2 ppm,  
27 which although not as sensitive as atomic absorption spectroscopy, was able to detect  
28 significant differences in mineralisation, which are likely to be clinically relevant.

## 1 4.2 Efficacy studies

2 Previous Time-of-Flight Secondary Ion Mass Spectrometry studies of the AUC  
3 demonstrated the presence of the three antimicrobials distributed evenly throughout the  
4 silicone and that they are able to diffuse through it [11]. This appears to be consistent with  
5 the results found here in that antimicrobials are likely able to diffuse from the catheter into  
6 the conditioning film and they are able to replace molecules at the surface that are rinsed  
7 away by flow over 12 weeks, suggesting that the conditioning film becomes *de facto* the  
8 secondary antimicrobial surface. If the antimicrobials were unable to diffuse through the  
9 silicone to replace lost drug molecules, a consistent killing effect of the catheter over 12  
10 weeks would not be observed. The catheters containing *P. mirabilis* were chosen for the  
11 XPS studies as *P. mirabilis* forms a robust crystalline biofilm which would increase the  
12 thickness of the surface deposits. This was considered a 'worst case scenario' of mineral  
13 deposition on the surface and would be a conservative indicator of the ability of the  
14 antimicrobial drug molecules to migrate through the surface accretions.

15 Success in the in vitro flow model was conservatively determined as bacterial  
16 eradication, but in vivo a significant reduction might be considered a success in certain  
17 clinical circumstances. 20% TSB was chosen as the perfusion medium as the constituent  
18 peptide content at this concentration was equivalent to that of urine and the medium is  
19 readily available in the large quantities needed. Furthermore, TSB does not readily form  
20 crystals on the catheter surfaces, which was important so that the AUCs did not block during  
21 the 12 week period of constant medium perfusion, as this assay was measuring bacterial  
22 attachment and not propensity for mineral encrustation. These studies contribute to the  
23 confidence in the ability to prevent colonisation as previous studies have tested other ESBL  
24 *E. coli* and MRSA strains, which also demonstrated 12 weeks of protection under flow  
25 conditions [11].

### 1 4.3 In vivo studies

2 All antimicrobials impregnated into the catheter have been used extensively clinically  
3 and therefore their safety profile is well-established. However, the in vivo safety of our  
4 antimicrobial-impregnation technology has been verified elsewhere. For example, segments  
5 of a continuous ambulatory peritoneal dialysis catheter impregnated using the same method  
6 but containing rifampicin, triclosan, and trimethoprim were implanted intraperitoneally in  
7 mice. At surgery there were only minimal inflammatory changes seen, attributable to the  
8 surgical implantation, and there were no differences in inflammatory reactions at 7 and 31  
9 days between the control and antimicrobial-impregnated segments[20]. A hydrocephalus  
10 shunt and external ventricular drain impregnated with rifampicin and clindamycin by this  
11 method are in use clinically in 47 countries with no reports of adverse events [43, 44].  
12 Importantly, a pilot tolerability and patient acceptability human clinical trial of the AUC  
13 reported here has recently been completed in 30 patients with results showing that the AUC  
14 is safe and acceptable to patients with no evidence of toxic or inflammatory reaction[45].

15

## 16 5 Conclusions

17 The impregnation process of silicone urinary catheters with three antimicrobials does  
18 not increase the surface roughness of the catheter surface. Studies of phosphate deposition  
19 on the catheter surfaces in an initial static model and then a perfusion model demonstrated  
20 that when inoculated with *P. mirabilis* phosphate deposition was significantly reduced on the  
21 AUCs. When exposed to other conditions such as incubation with AU adjusted to three pH  
22 values and when inoculated with *S. saprophyticus* and *E. coli*, there were no differences in  
23 phosphate deposition on the AUC catheters and segments. The AUC may increase the time  
24 to blockage in clinical use by reduction of mineral deposition caused by *P. mirabilis*.

25 To the authors' knowledge, this is the first antimicrobial catheter technology with 12  
26 weeks of protective activity against carbapenemase – producing (NDM-1) *E. coli*.  
27 Investigations into its mechanism of action show that the antimicrobials are eluted over the

1 12 week period of use and that they are able to migrate into bacterial and non-bacterial  
2 conditioning films that form on the catheter surface to prevent bacterial colonisation. These  
3 results suggest that the AUC may prevent CAUTI including by MDR organisms and reduce  
4 mineral encrustation in long-term urinary catheter use. This would reduce antibiotic  
5 prescribing and associated side effects and avoid development of resistance [20], as well as  
6 the need for early catheter changes due to blocked catheters which have a significant impact  
7 on a patient's quality of life. In vivo studies have shown that the formulation used in the  
8 catheter is safe for human use.

9

#### 10 **Supplementary Material:**

11 The following material is supplied as supporting information:

- 12 - Supplementary Method 1: Bacterial attachment assay method
- 13 - Supplementary Method 2: High-performance liquid chromatography of antimicrobial  
14 urinary catheter segments method
- 15 - Supplementary Table 1: Maintenance tryptone soya broth concentrations per test  
16 isolate used in the bacterial attachment assay

17

#### 18 **Acknowledgements:**

19 We would like to acknowledge Paul Cooling for his assistance in refining the high-  
20 performance liquid chromatography protocol.

21

#### 22 **Funding:**

23 This is independent research funded by the National Institute for Health Research (NIHR)  
24 under its Invention for Innovation (i4i) Programme (Grant Reference Number II-LA-0214-  
25 20007). The views expressed are those of the authors and not necessarily those of the NHS,  
26 the NIHR or the Department of Health. Further information can be found at [www.nihr.ac.uk](http://www.nihr.ac.uk)

27

28

1 **Data Availability:**

2 The raw/processed data required to reproduce these findings cannot be shared at this time  
3 as the data also forms part of an ongoing study.

4  
5 **References:**

- 6  
7 [1] N.S. Morris, D.J. Stickler, C. Winters, Which indwelling urethral catheters resist  
8 encrustation by *Proteus mirabilis* biofilms?, Br J Urol 80(1) (1997) 58-63.
- 9 [2] D. Stickler, Clinical complications of urinary catheters caused by crystalline biofilms:  
10 something needs to be done, J Intern Med 276(2) (2014) 120-129.
- 11 [3] N.S. Morris, D.J. Stickler, Encrustation of indwelling urethral catheters by *Proteus*  
12 *mirabilis* biofilms growing in human urine, J Hosp Infect 39(3) (1998) 227-34.
- 13 [4] C.M. Kunin, Q.F. Chin, S. Chambers, Indwelling urinary catheters in the elderly. Relation  
14 of "catheter life" to formation of encrustations in patients with and without blocked catheters,  
15 Am J Med 82(3) (1987) 405-411.
- 16 [5] B.D. Jones, H.L. Mobley, Genetic and biochemical diversity of ureases of *Proteus*,  
17 *Providencia*, and *Morganella* species isolated from urinary tract infection, Infect Immun 55(9)  
18 (1987) 2198-203.
- 19 [6] N. Holling, C. Dedi, C.E. Jones, J.A. Hawthorne, G.W. Hanlon, J.P. Salvage, B.A. Patel,  
20 L.M. Barnes, B.V. Jones, Evaluation of environmental scanning electron microscopy for  
21 analysis of *Proteus mirabilis* crystalline biofilms in situ on urinary catheters, Fems  
22 Microbiology Letters 355(1) (2014) 20-27.
- 23 [7] A.J. Dumanski, H. Hedelin, A. Edin-Liljegren, D. Beauchemin, R.J. McLean, Unique  
24 ability of the *Proteus mirabilis* capsule to enhance mineral growth in infectious urinary calculi,  
25 Infect Immun 62(7) (1994) 2998-3003.



- 1 [8] P. Tambyah, V. Knasinski, D. Maki, The direct costs of nosocomial catheter-associated  
2 urinary tract infection in the era of managed care, *Infect Control Hosp Epidemiol* 23(1)  
3 (2002) 27-31.
- 4 [9] R. Pickard, T. Lam, G. MacLennan, K. Starr, M. Kilonzo, G. McPherson, K. Gillies, A.  
5 McDonald, K. Walton, B. Buckley, C. Glazener, C. Boachie, J. Burr, J. Norrie, L. Vale, A.  
6 Grant, J. N'Dow, Antimicrobial catheters for reduction of symptomatic urinary tract infection  
7 in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled  
8 trial, *Lancet* 380(9857) (2012) 1927-1935.
- 9 [10] National Institute for Health and Care Excellence, Farco-fill Protect for urinary  
10 catheterisation: Medtech innovation briefing, NICE Advice, 2017.
- 11 [11] L.E. Fisher, A.L. Hook, W. Ashraf, A. Yousef, D.A. Barrett, D.J. Scurr, X. Chen, E.F.  
12 Smith, M. Fay, C.D. Parmenter, R. Parkinson, R. Bayston, Biomaterial modification of urinary  
13 catheters with antimicrobials to give long-term broadspectrum antibiofilm activity, *J Control*  
14 *Release* 202 (2015) 57-64.
- 15 [12] L. Fisher Development and evaluation of an antimicrobial urinary catheter, PhD Thesis,  
16 University of Nottingham, 2011.
- 17 [13] X. Zhao, K. Drlica, Restricting the selection of antibiotic-resistant mutants: a general  
18 strategy derived from fluoroquinolone studies, *Clin Infect Dis* 33(Supplement\_3) (2001)  
19 S147-S156.
- 20 [14] R. Bayston , W. Ashraf, C. Bhundia, Mode of action of an antimicrobial biomaterial for  
21 use in hydrocephalus shunts, *J Antimicrob Chemother* 53(5) (2004) 778-82.
- 22 [15] R. Bayston, R.D. Milner, Antimicrobial activity of silicone rubber used in hydrocephalus  
23 shunts, after impregnation with antimicrobial substances, *J Clin Pathol* 34(9) (1981) 1057-62.

- 1 [16] European Committee on Antimicrobial Susceptibility Testing, EUCAST guidelines for  
2 detection of resistance mechanisms and specific resistances of clinical and/or  
3 epidemiological importance v2.0, 2017. [http://www.eucast.org/resistance\\_mechanisms/](http://www.eucast.org/resistance_mechanisms/).
- 4 [17] European Committee on Antimicrobial Susceptibility Testing, Antimicrobial susceptibility  
5 testing: EUCAST disc diffusion method v5.0, January, 2015.
- 6 [18] NDM-1 in patient with no obvious travel or health care history, Health Protection  
7 Scotland Weekly Report, 2012, p. 400.
- 8 [19] R. Bayston, E. Lambert, Duration of protective activity of cerebrospinal fluid shunt  
9 catheters impregnated with antimicrobial agents to prevent bacterial catheter-related  
10 infection, J Neurosurg 87(2) (1997) 247-51.
- 11 [20] R. Bayston, L. Fisher, K. Weber, An antimicrobial modified silicone peritoneal catheter  
12 with activity against both Gram-positive and Gram-negative bacteria, Biomaterials 30(18)  
13 (2009) 3167-3173.
- 14 [21] M. Daniel, Otitis media with effusion: current treatment, new understanding of its  
15 aetiopathogenesis, and a novel therapeutic approach, PhD Thesis, University of Nottingham,  
16 2012.
- 17 [22] D.P. Griffith, D.M. Musher, C. Itin, Urease. The primary cause of infection-induced  
18 urinary stones, Invest Urol 13(5) (1976) 346-50.
- 19 [23] K. Diem, Documenta Geigy; Scientific Tables, Geigy (U.K.) Limited Pharmaceuticals  
20 Division, Macclesfield, Cheshire, 1962.
- 21 [24] M. Mahadevaiah, Y. Kumar, M. Galil, M. Suresha, M. Sathish, G. Nagendrappa, A  
22 simple spectrophotometric determination of phosphate in sugarcane juices, water, and  
23 detergent samples, E-J Chem 4(4) (2007) 467-473.

- 1 [25] R. Bayston, N. Grove, J. Siegel, D. Lawellin, S. Barsham, Prevention of hydrocephalus  
2 shunt catheter colonisation in vitro by impregnation with antimicrobials, *J Neurol Neurosurg*  
3 *Psychiatry* 52(5) (1989) 605-9.
- 4 [26] S.K.S. Choong, S. Wood, H.N. Whitfield, A model to quantify encrustation on ureteric  
5 stents, urethral catheters and polymers intended for urological use, *BJU International* 86(4)  
6 (2000) 414-421.
- 7 [27] Gusnaniar, F. Hizal, C.-H. Choi, J. Sjollema, T. Nuryastuti, M. Rustema-Abbing, R.T.  
8 Rozenbaum, H.C. van der Mei, H.J. Busscher, S.W. Wessel, Transmission of monospecies  
9 and dual-species biofilms from smooth to nanopillared surfaces, *Appl Environ Microbiol*  
10 84(15) (2018) e01035-18.
- 11 [28] Institute of Medicine (US) Committee on the Safety of Silicone Breast Implants, 2,  
12 *Silicone Chemistry*, in: S.E. Bondurant, V; Herdman, R (Ed.), *Safety of Silicone Breast*  
13 *Implants*, National Academies Press (US), Washington (DC), 1999.
- 14 [29] J.M. Ouyang, Identification of Urinary Stone Components by X-Ray Photoelectron  
15 Spectroscopy, *Spectroscopy Letters* 37(6) (2004) 633-641.
- 16 [30] P.G. Rouxhet, N. Mozes, P.B. Dengis, Y.F. Dufrêne, P.A. Gerin, M.J. Genet, Application  
17 of X-ray photoelectron spectroscopy to microorganisms, *Colloids and Surfaces B:*  
18 *Biointerfaces* 2(1) (1994) 347-369.
- 19 [31] P. Cubillas, M. Anderson, Chapter 1. Synthesis mechanisms: crystal growth and  
20 nucleation 1, in: J.C. Cejika, A; Zones, S (Ed.), *Zeolites and Catalysis: Synthesis Reactions*  
21 *and Applications*, Wiley-VCH, Weinheim, Germany, 2010, pp. 1-55.
- 22 [32] D. Erdemir, A.Y. Lee, A.S. Myerson, Nucleation of crystals from solution: classical and  
23 two-step models, *Acc Chem Res* 42(5) (2009) 621-629.

- 1 [33] M. Santin, A. Motta, S.P. Denyer, M. Cannas, Effect of the urine conditioning film on  
2 ureteral stent encrustation and characterization of its protein composition, *Biomaterials*  
3 20(13) (1999) 1245-1251.
- 4 [34] B.K. Canales, L. Higgins, T. Markowski, L. Anderson, Q.A. Li, M. Monga, Presence of  
5 five conditioning film proteins are highly associated with early stent encrustation, *J Endourol*  
6 23(9) (2009) 1437-1442.
- 7 [35] C. Tieszer, G. Reid, J. Denstedt, XPS and SEM detection of surface changes on 64  
8 ureteral stents after human usage, *J Biomed Mater Res A* 43(3) (1998) 321-330.
- 9 [36] J. Prywer, A. Torzewska, Bacterially induced struvite growth from synthetic urine:  
10 experimental and theoretical characterization of crystal morphology, *Cryst Growth Des* 9(8)  
11 (2009) 3538-3543.
- 12 [37] Urinalysis, EClinPath, College of Veterinary Medicine, Cornell University, [Electronic],  
13 2013.
- 14 [38] N. Morris, D. Stickler, C. Winters, Which indwelling urethral catheters resist encrustation  
15 by *Proteus mirabilis* biofilms?, *Br J Urol* 80(1) (1997) 58-63.
- 16 [39] S.M. Macleod, D.J. Stickler, Species interactions in mixed-community crystalline biofilms  
17 on urinary catheters, *J Med Microbiol* 56(Pt 11) (2007) 1549-57.
- 18 [40] A.P. Udoh, Determination of calcium, magnesium and zinc in unused lubricating oils by  
19 atomic absorption spectroscopy, *Talanta* 42(12) (1995) 1827-1831.
- 20 [41] P. Gupta, R. Ramchandran, Atomic absorption spectrometric method for the  
21 determination of phosphorus using the bismuth-phosphomolybdate complex, *J Anal At*  
22 *Spectrom* 2(4) (1987) 413-414.

1 [42] G. Krupadanam, D. Prasad, K. Rao, K. Reddy, C. Sudhakar, Chapter 4: Instrumental  
2 methods of analysis: Ultraviolet-visible spectroscopy, Analytical Chemistry, Universities  
3 Press (India) Private Limited, Hyderabad 2004.


4 [43] K.M. Winkler, C.M. Woernle, M. Seule, U. Held, R.L. Bernays, E. Keller, Antibiotic-  
5 impregnated versus silver-bearing external ventricular drainage catheters: preliminary results  
6 in a randomized controlled trial, Neurocritical care 18(2) (2013) 161-5.

7 [44] G.K. Wong, M. Ip, W.S. Poon, C.W. Mak, R.Y. Ng, Antibiotics-impregnated ventricular  
8 catheter versus systemic antibiotics for prevention of nosocomial CSF and non-CSF  
9 infections: a prospective randomised clinical trial, J Neurol Neurosurg Psychiatry 81(10)  
10 (2010) 1064-7.

11 [45] K. Belfield, H. Betts, R. Parkinson, R. Bayston, A tolerability and patient acceptability  
12 pilot study of a novel antimicrobial urinary catheter for long-term use, Neurourol Urodyn  
13 (2018) 1-8.

14 **Figure Legends:**


15 **Figure 1:** Diagram of the set-up of the in vitro flow model. Tubing is labelled numerically and  
16 apparatus are labelled alphabetically. Components include A. artificial urine or tryptone soya  
17 broth reservoir, B. peristaltic pump, C: multichannel water jacket, D: waste collection  
18 container. 1: reservoir tubing, 2: pump tubing, 3: urinary catheter (silicone or antimicrobial),  
19 4: Outlet tubing



20


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

**Figure 2.** Atomic force microscopy results of silicone (plain) and antimicrobial-impregnated urinary catheter (AUC) 1.0 cm longitudinally cut segments soaked in artificial urine (AU) for 1 hour, 1 week, or 2 weeks with controls. a) AFM 3D height sensor images representative of each group. For a better view of topographic details, the vertical (Z) and lateral (X-Y) dimensions are not proportionally plotted. b)  $R_q$  values (nm) in triplicate with standard deviation.



15 Fig 2a  
16


b)




1  
2  
3 Fig 2b

4  
5  
6  
7  
8 **Figure 3:** Mean phosphate (complete line) (mg/L) and standard deviation in AU a) adjusted  
9 to varying pH values or b) inoculated with bacteria overlaid with pH of the AU (dotted line)

10  
11




12  
13  
14 **Figure 4:** Phosphate (mg/L) attached to silicone and antimicrobial impregnated catheter  
15 (AUC) segments incubated statically with a) artificial urine (AU) inoculated bacteria or b) pH-  
16 adjusted artificial urine (AU).



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12


**Figure 5:** Scanning electron microscopy images of the lumens of a) silicone and b) antimicrobial impregnated catheters perfused with artificial urine and inoculated with *P. mirabilis* visualised at x65 magnification. Silicone catheters and AUCs are matched and imaged at the day of blockage of control.





1  
2  
3  
4  
5  
6  
7  
8  
9  
10


**Figure 6:** Examples of colonisation of silicone controls and antimicrobial urinary catheters (AUCs) by a) NDM-1 producing *E. coli* (data displayed as mean CFU/mL with SD), b.) MRSA (data display \*point of failure of one AUC, +point of failure of a second AUC, Syringe symbol indicates point of bacterial challenge of catheters. c) antimicrobial impregnated catheter segment after 12 weeks of bacterial inoculation and perfusion and d) silicone catheter segment one week after bacterial inoculation and perfusion.




1  
2  
3  
4  
5  
6  
7  
8

**Figure 7:** N 1s peaks generated by x-ray photoelectron spectroscopy. AU: artificial urine;  
*Proteus mirabilis*  
 Graphic

Antimicrobial urinary catheter (AUC)





All-silicone control (Plain)



Perfused with AU and Proteus

Perfused with AU only



1  
2  
3

## Supplementary material

### **An antimicrobial impregnated urinary catheter that reduces mineral encrustation and prevents colonisation by multi-drug resistant organisms, for up to 12 weeks**

*Katherine Belfield<sup>1</sup>, Xingyong Chen<sup>2</sup>, Emily F. Smith<sup>3</sup>, Waheed Ashraf<sup>1</sup>, Roger Bayston<sup>1\*</sup>*

1. Biomaterials-Related Infection Group, School of Medicine, University of Nottingham, Nottingham, United Kingdom
2. School of Pharmacy, University of Nottingham, Nottingham, United Kingdom
3. Nanoscale and Microscale Research Centre, School of Chemistry, University of Nottingham, Nottingham, United Kingdom

\*Corresponding Author:


Professor Roger Bayston

Email: [roger.bayston@nottingham.ac.uk](mailto:roger.bayston@nottingham.ac.uk)

Telephone: +44 1158231115

*Supplementary Methods*

**Graphical Abstract:**



Drug molecules migrate  
to the surface to replace  
those lost to flow

Catheter silicone matrix